Work

Abstract P031: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with de-differentiated liposarcoma

Year: 2021

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-21-p031

Authors: Mrinal Gounder, Gary Schwartz, Robin Jones, Shreyaskumar Patel, Silvia Stacchiotti, Andrew Wagner, Vijaya Tirunagaru, Naisargee Shah, Richard Bryce, Robert Doebele

Institutions: Memorial Sloan Kettering Cancer Center, Columbia University Irving Medical Center, Columbia University, Institute of Cancer Research, Royal Marsden Hospital, The University of Texas MD Anderson Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Dana-Farber Cancer Institute

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200593165

Cites:

Cited by:

Related to: 10